{"id":"gemcitabine-gem","safety":{"commonSideEffects":[{"rate":"60–80","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"70","effect":"Nausea and vomiting"},{"rate":"65","effect":"Fatigue"},{"rate":"41","effect":"Fever"},{"rate":"30","effect":"Rash"},{"rate":"67","effect":"Elevated liver enzymes"},{"rate":null,"effect":"Hemolytic uremic syndrome (rare)"}]},"_chembl":null,"_dailymed":{"setId":"b9347b14-7ca2-43f5-9ee8-7ba709ae6b52","title":"GEMCITABINE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [FRESENIUS KABI USA, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemcitabine is a deoxycytidine analog that is phosphorylated intracellularly to its active triphosphate form. It inhibits ribonucleotide reductase, reducing deoxyribonucleotide pools, and is incorporated into DNA during replication, leading to chain termination and apoptosis. It is particularly effective against rapidly dividing cells.","oneSentence":"Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:54.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer"},{"name":"Non-small cell lung cancer"},{"name":"Breast cancer"},{"name":"Ovarian cancer"},{"name":"Bladder cancer"}]},"trialDetails":[{"nctId":"NCT04910386","phase":"PHASE2","title":"Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers","status":"NOT_YET_RECRUITING","sponsor":"3D Medicines (Sichuan) Co., Ltd.","startDate":"2027-06-01","conditions":"Biliary Tract Neoplasms","enrollment":126},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT07480850","phase":"PHASE2","title":"Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":40},{"nctId":"NCT07322263","phase":"PHASE2","title":"Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Michael A. O'Donnell","startDate":"2026-04-01","conditions":"Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma","enrollment":174},{"nctId":"NCT01679119","phase":"PHASE2","title":"Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-10","conditions":"Diffuse Large B Cell Lymphoma","enrollment":129},{"nctId":"NCT03547973","phase":"PHASE2","title":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2018-08-13","conditions":"Metastatic Urothelial Cancer","enrollment":827},{"nctId":"NCT07459296","phase":"PHASE3","title":"Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-03-05","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":266},{"nctId":"NCT05601323","phase":"NA","title":"A Study of Suizenji in Patients With Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SONIRE Therapeutics Inc.","startDate":"2023-01-31","conditions":"Unresectable Pancreatic Cancer","enrollment":90},{"nctId":"NCT03816163","phase":"PHASE2","title":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2019-03-15","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":393},{"nctId":"NCT06239727","phase":"PHASE3","title":"Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Nasopharyngeal Carcinoma","enrollment":593},{"nctId":"NCT07444541","phase":"PHASE1, PHASE2","title":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anova Innovation Limited","startDate":"2026-03","conditions":"Pancreatic Cancer","enrollment":84},{"nctId":"NCT03652428","phase":"PHASE1, PHASE2","title":"Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2019-04-02","conditions":"Locally Advanced Pancreatic Cancer","enrollment":24},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT04104672","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2019-11-06","conditions":"Advanced Pancreatic Cancer","enrollment":196},{"nctId":"NCT05644041","phase":"PHASE2","title":"Intravesical Gem/Doce in Patients With NMIBC","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2023-03-01","conditions":"Urinary Bladder Cancer","enrollment":25},{"nctId":"NCT06960577","phase":"PHASE3","title":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-15","conditions":"Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate","enrollment":150},{"nctId":"NCT06290687","phase":"PHASE2","title":"Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-02-18","conditions":"Malignant Neoplasm of Bladder, Muscle Invasive Bladder Carcinoma","enrollment":40},{"nctId":"NCT07044453","phase":"PHASE2, PHASE3","title":"Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2025-12-08","conditions":"Resected Pancreatic Adenocarcinoma","enrollment":390},{"nctId":"NCT07383922","phase":"PHASE3","title":"A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","startDate":"2026-02-28","conditions":"Pancreatic Cancer","enrollment":524},{"nctId":"NCT07385079","phase":"PHASE3","title":"Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-01","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer","enrollment":412},{"nctId":"NCT05634369","phase":"PHASE1, PHASE2","title":"A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-11-14","conditions":"Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed","enrollment":50},{"nctId":"NCT07325539","phase":"PHASE2","title":"LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-01","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer","enrollment":55},{"nctId":"NCT07235202","phase":"PHASE1, PHASE2","title":"A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy","status":"RECRUITING","sponsor":"Shenzhen Majory Biotechnology Co., Ltd.","startDate":"2025-12-24","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":45},{"nctId":"NCT02151084","phase":"PHASE2","title":"A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2014-11","conditions":"Biliary Tract Carcinoma, Gallbladder Carcinoma","enrollment":57},{"nctId":"NCT02364713","phase":"PHASE2","title":"MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-03-13","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":17},{"nctId":"NCT06822010","phase":"PHASE2","title":"SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2026-06-01","conditions":"Urinary Bladder Cancer, Upper Tract Urothelial Cancer, Urothelial Cancer","enrollment":28},{"nctId":"NCT05085548","phase":"PHASE1","title":"ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"ProDa BioTech, LLC","startDate":"2021-10-29","conditions":"Advanced Pancreatic Cancer, Solid Tumor Malignancies","enrollment":58},{"nctId":"NCT05325281","phase":"PHASE1","title":"CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2022-10-31","conditions":"Pancreas Adenocarcinoma","enrollment":8},{"nctId":"NCT04787991","phase":"PHASE1","title":"Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Cancer Insight, LLC","startDate":"2021-08-09","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":45},{"nctId":"NCT07189793","phase":"PHASE2","title":"Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10","conditions":"Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder","enrollment":106},{"nctId":"NCT07129772","phase":"PHASE2","title":"Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-11-01","conditions":"Nasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC)","enrollment":53},{"nctId":"NCT07155629","phase":"PHASE3","title":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2025-09-01","conditions":"Pancreatic Cancer Resectable","enrollment":381},{"nctId":"NCT04871321","phase":"","title":"Biomarker Discovery in Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"CHA University","startDate":"2021-04-14","conditions":"Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer","enrollment":119},{"nctId":"NCT05239182","phase":"PHASE2","title":"9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma","status":"TERMINATED","sponsor":"Anwaar Saeed","startDate":"2022-01-26","conditions":"Pancreatic Adenocarcinoma","enrollment":7},{"nctId":"NCT05712694","phase":"PHASE3","title":"Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)","status":"RECRUITING","sponsor":"Polaris Group","startDate":"2023-11-29","conditions":"Soft Tissue Sarcoma","enrollment":300},{"nctId":"NCT03984357","phase":"PHASE2","title":"Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-03-16","conditions":"Nasopharyngeal Carcinoma","enrollment":152},{"nctId":"NCT04907370","phase":"PHASE3","title":"PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":532},{"nctId":"NCT04796220","phase":"PHASE1","title":"Focused Ultrasound and Gemcitabine in Breast Cancer","status":"RECRUITING","sponsor":"Patrick Dillon, MD","startDate":"2022-01-27","conditions":"Breast Cancer, Breast Neoplasms","enrollment":32},{"nctId":"NCT06897644","phase":"PHASE3","title":"Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2025-03-27","conditions":"Pancreatic Adenocarcinoma Advanced or Metastatic","enrollment":340},{"nctId":"NCT02807181","phase":"PHASE2, PHASE3","title":"SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma","status":"TERMINATED","sponsor":"Sirtex Medical","startDate":"2017-02-14","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":89},{"nctId":"NCT06963060","phase":"PHASE2","title":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","status":"ENROLLING_BY_INVITATION","sponsor":"Wei Gong","startDate":"2024-06-01","conditions":"Gallbladder Cancer, Cholangiocarcinoma","enrollment":44},{"nctId":"NCT03468335","phase":"PHASE3","title":"2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-03-31","conditions":"Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":151},{"nctId":"NCT06493552","phase":"PHASE2, PHASE3","title":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","status":"RECRUITING","sponsor":"Vasgene Therapeutics, Inc","startDate":"2025-03-15","conditions":"Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma","enrollment":700},{"nctId":"NCT05776524","phase":"PHASE2","title":"Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"THERABIONIC INC.","startDate":"2023-06-13","conditions":"Pancreatic Cancer, Metastatic Adenocarcinoma","enrollment":46},{"nctId":"NCT02506959","phase":"PHASE2","title":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma","enrollment":83},{"nctId":"NCT05655949","phase":"PHASE2","title":"Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2024-02-13","conditions":"Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable","enrollment":30},{"nctId":"NCT01648023","phase":"PHASE2","title":"Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin","status":"COMPLETED","sponsor":"Robert C. Martin","startDate":"2012-07","conditions":"Unresectable Intrahepatic Cholangiocarcinoma","enrollment":49},{"nctId":"NCT02202772","phase":"PHASE1, PHASE2","title":"Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guarionex J. Decastro","startDate":"2014-12-01","conditions":"Urothelial Carcinoma of the Urinary Bladder","enrollment":51},{"nctId":"NCT06789679","phase":"PHASE2","title":"Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-01-25","conditions":"Pancreatic Adenocarcinoma","enrollment":128},{"nctId":"NCT03317158","phase":"PHASE1, PHASE2","title":"Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder","status":"RECRUITING","sponsor":"Noah Hahn, M.D.","startDate":"2017-11-21","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":55},{"nctId":"NCT04308174","phase":"PHASE2","title":"Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Asan Medical Center","startDate":"2020-05-20","conditions":"Biliary Tract Neoplasms, Gallbladder Cancer, Cholangiocarcinoma","enrollment":45},{"nctId":"NCT05587374","phase":"PHASE3","title":"Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-08-01","conditions":"Nasopharyngeal Carcinoma, Nasopharyngeal Cancer","enrollment":490},{"nctId":"NCT06349889","phase":"PHASE2","title":"Adebrelimab and Chemoradiotherapy in High-risk LANPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-23","conditions":"Nasopharyngeal Carcinoma, Nasopharyngeal Cancer","enrollment":50},{"nctId":"NCT05861336","phase":"PHASE2","title":"GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2023-06-14","conditions":"Pancreatic Cancer","enrollment":""},{"nctId":"NCT05314998","phase":"PHASE3","title":"Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature","status":"NOT_YET_RECRUITING","sponsor":"John Neoptolemos","startDate":"2025-01-15","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":394},{"nctId":"NCT03252808","phase":"PHASE1","title":"Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takara Bio Inc.","startDate":"2017-09-25","conditions":"Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV","enrollment":36},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT06017297","phase":"PHASE2","title":"Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma","status":"WITHDRAWN","sponsor":"Georgetown University","startDate":"2024-12","conditions":"Borderline Resectable Carcinoma, Biliary Tract Cancer","enrollment":""},{"nctId":"NCT06341764","phase":"PHASE2","title":"Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2023-09-01","conditions":"Cholangiocarcinoma","enrollment":38},{"nctId":"NCT06669013","phase":"PHASE3","title":"Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2021-05-20","conditions":"Bone Sarcoma, Embryonal Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma","enrollment":40},{"nctId":"NCT06505486","phase":"","title":"GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-07-10","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":21},{"nctId":"NCT02295722","phase":"PHASE1, PHASE2","title":"GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2015-04","conditions":"Hodgkin's Lymphoma - Relapsed/Refractory, Non-Hodgkin's Lymphoma - Aggressive, Follicular Lymphoma","enrollment":100},{"nctId":"NCT03887130","phase":"PHASE2","title":"Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2007-03-27","conditions":"Breast Cancer","enrollment":152},{"nctId":"NCT04669899","phase":"PHASE1, PHASE2","title":"Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors","status":"COMPLETED","sponsor":"Jounce Therapeutics, Inc.","startDate":"2021-01-12","conditions":"Cancer","enrollment":190},{"nctId":"NCT05064618","phase":"PHASE1, PHASE2","title":"Investigator-initiated Clinical Trial of MIKE-1","status":"RECRUITING","sponsor":"Nagoya University","startDate":"2021-08-23","conditions":"Pancreatic Cancer","enrollment":55},{"nctId":"NCT05671900","phase":"NA","title":"Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Clinical Hospital Centre Zagreb","startDate":"2020-04-01","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":70},{"nctId":"NCT04617067","phase":"PHASE2","title":"Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2020-10-16","conditions":"Advanced Pancreatic Cancer","enrollment":15},{"nctId":"NCT05820906","phase":"PHASE2","title":"Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-09-01","conditions":"Advanced Biliary Tract Cancer","enrollment":30},{"nctId":"NCT05738057","phase":"PHASE2","title":"Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Hua Li","startDate":"2023-06-30","conditions":"Unresectable Intrahepatic Cholangiocarcinoma","enrollment":22},{"nctId":"NCT05781958","phase":"PHASE2","title":"Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC","status":"UNKNOWN","sponsor":"Shen Feng","startDate":"2022-11-24","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":64},{"nctId":"NCT03912818","phase":"PHASE2","title":"Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer","status":"TERMINATED","sponsor":"Stanford University","startDate":"2019-04-10","conditions":"Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma","enrollment":7},{"nctId":"NCT05979298","phase":"PHASE2","title":"Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer","status":"UNKNOWN","sponsor":"CureLab Oncology","startDate":"2019-11-15","conditions":"Ovarian Cancer, Platinum-resistant Ovarian Cancer","enrollment":40},{"nctId":"NCT05869474","phase":"NA","title":"Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2023-08-01","conditions":"Metastatic Pancreatic Cancer","enrollment":206},{"nctId":"NCT05083247","phase":"PHASE2","title":"Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Erasme University Hospital","startDate":"2023-03-24","conditions":"Pancreatic Neoplasm, Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":256},{"nctId":"NCT05251038","phase":"PHASE1, PHASE2","title":"Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer","status":"WITHDRAWN","sponsor":"Devalingam Mahalingam","startDate":"2022-09-13","conditions":"Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":""},{"nctId":"NCT03126435","phase":"PHASE3","title":"EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX","status":"COMPLETED","sponsor":"SynCore Biotechnology Co., Ltd.","startDate":"2018-10-16","conditions":"Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma","enrollment":218},{"nctId":"NCT03790111","phase":"PHASE2","title":"A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer","status":"TERMINATED","sponsor":"TerSera Therapeutics LLC","startDate":"2019-03-13","conditions":"Biliary Tract Cancer (BTC)","enrollment":53},{"nctId":"NCT01802749","phase":"PHASE3","title":"Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2013-11","conditions":"Recurrent Ovarian Cancer","enrollment":406},{"nctId":"NCT05097209","phase":"PHASE2","title":"Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Wei Jiang","startDate":"2022-04-06","conditions":"Nasopharyngeal Carcinoma","enrollment":200},{"nctId":"NCT00385606","phase":"PHASE2, PHASE3","title":"Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2003-01","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT04289792","phase":"PHASE2","title":"Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University Union Hospital","startDate":"2020-05-09","conditions":"Pancreatic Neoplasms","enrollment":27},{"nctId":"NCT05717790","phase":"NA","title":"Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Fourth Affiliated Hospital of Guangxi Medical University","startDate":"2022-12-01","conditions":"Nasopharyngeal Carcinoma by AJCC V8 Stage","enrollment":288},{"nctId":"NCT02393248","phase":"PHASE1, PHASE2","title":"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2015-02-27","conditions":"Lung Cancer, Solid Tumor, Gastric Cancer","enrollment":201},{"nctId":"NCT03214250","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Parker Institute for Cancer Immunotherapy","startDate":"2017-07-21","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":129},{"nctId":"NCT03488251","phase":"PHASE2","title":"PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Molecular Templates, Inc.","startDate":"2018-08-20","conditions":"Non-hodgkin Lymphoma,B Cell, Refractory Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma","enrollment":8},{"nctId":"NCT03064854","phase":"PHASE1","title":"PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-05-24","conditions":"Non-small Cell Lung Cancer","enrollment":111},{"nctId":"NCT04769414","phase":"PHASE2","title":"Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2021-02-20","conditions":"Cancer of Pancreas, Chemotherapy Effect, Metastatic Pancreatic Cancer","enrollment":48},{"nctId":"NCT03251313","phase":"PHASE1","title":"PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-05-15","conditions":"Triple Negative Breast Cancer","enrollment":31},{"nctId":"NCT03062059","phase":"PHASE2","title":"The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2018-03-01","conditions":"Urothelial Carcinoma","enrollment":134},{"nctId":"NCT03086993","phase":"PHASE2, PHASE3","title":"Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Delcath Systems Inc.","startDate":"2018-04-10","conditions":"Bile Duct Cancer, Intrahepatic Cholangiocarcinoma","enrollment":295},{"nctId":"NCT01360593","phase":"PHASE2","title":"Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"David A. Clump, MD, PhD","startDate":"2011-07-25","conditions":"Pancreatic Cancer","enrollment":35},{"nctId":"NCT02125136","phase":"PHASE2","title":"Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-11","conditions":"Ductal Adenocarcinoma of the Pancreas","enrollment":168},{"nctId":"NCT02128282","phase":"PHASE1, PHASE2","title":"Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma","status":"COMPLETED","sponsor":"Senhwa Biosciences, Inc.","startDate":"2014-06","conditions":"Cholangiocarcinoma","enrollment":127},{"nctId":"NCT04707118","phase":"PHASE1","title":"Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-02-23","conditions":"Advanced Pancreatic Cancer","enrollment":106},{"nctId":"NCT03613168","phase":"PHASE2","title":"Trastuzumab in HER2-positive Biliary Tract Cancer","status":"COMPLETED","sponsor":"Changhoon Yoo","startDate":"2019-06-01","conditions":"Cholangiocarcinoma, Biliary Tract Cancer, HER-2 Protein Overexpression","enrollment":4},{"nctId":"NCT02717091","phase":"PHASE2","title":"Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer","status":"UNKNOWN","sponsor":"Nagoya University","startDate":"2015-07","conditions":"Borderline Resectable Pancreatic Cancer","enrollment":50},{"nctId":"NCT01012297","phase":"PHASE3","title":"Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-11","conditions":"Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma","enrollment":107},{"nctId":"NCT01839487","phase":"PHASE2","title":"PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2013-05-14","conditions":"Metastatic Pancreatic Cancer","enrollment":279},{"nctId":"NCT04216758","phase":"PHASE2","title":"Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-01-01","conditions":"Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma, Stage IIA Pancreatic Adenocarcinoma","enrollment":300},{"nctId":"NCT01836432","phase":"PHASE3","title":"Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2013-05","conditions":"Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm","enrollment":302}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1921,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GEM","Gemcitabine Hydrochloride","Gemcitabine"],"phase":"marketed","status":"active","brandName":"Gemcitabine (GEM)","genericName":"Gemcitabine (GEM)","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death. Used for Metastatic pancreatic cancer, Non-small cell lung cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}